Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous HX575 once weekly and every 2 weeks for anemia in chronic kidney disease
2008-002696-27Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Nov 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of epoetin alfa in anemia of renal disease and chronic kidney disease (CKD) (2 arms), sponsored by Hexal AG. Primary endpoint: Mean absolute change in hemoglobin level after 1:1 conversion from prior ESA to weekly HX575 and from weekly HX575 to fortnightly HX575. Started Nov 2008; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia of renal diseasechronic kidney disease (CKD)
Beyond the preview
Go deeper on 2008-002696-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002696-27.